سعر هيكترونين 200 مجم / 100 مل فيال 200 مل 2022

Ciprofloxacin 200 mg/100 ml solution for intravenous infusion, 200 ml vial.

• Skin and skin structure infections.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Bone and joint infections.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Complicated intra-abdominal infections (with metronidazole).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (≥1%): nausea, diarrhea, abnormal liver function tests, vomiting, CNS disturbances and rash; injection-site reactions may occur with IV use.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to ciprofloxacin, any other quinolone or product components.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Concomitant administration with tizanidine.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions occurring together, including tendinitis and tendon rupture, peripheral neuropathy and CNS effects, and may exacerbate muscle weakness in myasthenia gravis.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Serious and sometimes fatal hypersensitivity reactions and hepatotoxicity may occur; discontinue at the first sign of rash, jaundice or hypersensitivity.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• QT prolongation and torsade de pointes reported; avoid in known QT prolongation, hypokalemia and with other QT-prolonging drugs. Increased risk of aortic aneurysm/dissection, C. difficile-associated diarrhea and photosensitivity.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• TizanidineContraindicated: potentiation of hypotensive and sedative effects (ciprofloxacin inhibits CYP1A2).DailyMed (U.S. National Library of Medicine)
• TheophyllineAvoid: increased and prolonged theophylline exposure with risk of CNS and other serious adverse reactions; if unavoidable, monitor serum levels and adjust dose.DailyMed (U.S. National Library of Medicine)
• Drugs known to prolong the QT interval (class IA/III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics)Avoid: ciprofloxacin may further prolong the QT interval.DailyMed (U.S. National Library of Medicine)

• Decades of published experience with ciprofloxacin in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal/fetal outcomes; oral animal studies did not show fetal malformations.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Ciprofloxacin is present in human milk; because of potential serious adverse reactions in breastfed infants (including arthropathy in juvenile animals), breastfeeding is not recommended during treatment and for 2 days after the last dose, or milk may be pumped and discarded (anthrax post-exposure may justify continued breastfeeding).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Ciprofloxacin: Bactericidal fluoroquinolone that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV.